NCT06399341 - Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR). | Biotech Hunter

Enrollment

524

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions

Papillomavirus Infections

Interventions

DEVICE

Papilocare vaginal gel

Treatment with Papilocare® for 6 months (1 cannula/day for 21 days during first month + 1 cannula/alternate days for subsequent 5 months)

Trial Locations (4)

University General Hospital of Patra, Pátrai

University General Hospital of Larissa, Larissa

University General Hospital of Ioannina, Ioannina

"HIPPOKRATION General Hospital of Thessaloniki", Thessaloniki